spot_img
Tuesday, June 28, 2022
More
    HomeHealthSTAT+: The biggest losers from Medicare’s decision on Aduhelm may be Biogen’s...

    STAT+: The biggest losers from Medicare’s decision on Aduhelm may be Biogen’s competitors

    -



    Medicare could have launched a plan to limit entry to Biogen’s controversial Alzheimer’s drug, however the largest losers may very well be different drug makers readying therapies for the debilitating illness.

    The query is whether or not they encounter such difficulties and, in that case, to what extent?

    Continue to STAT+ to read the full story…



    Source link

    Related articles

    Stay Connected

    0FansLike
    0FollowersFollow
    3,373FollowersFollow
    0SubscribersSubscribe
    spot_img

    Latest posts